Marshall Wace, LLP Xenon Pharmaceuticals Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

A detailed history of Marshall Wace, LLP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,195,480 shares of XENE stock, worth $46.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,195,480
Previous 1,384,674 13.66%
Holding current value
$46.5 Million
Previous $54 Million 12.87%
% of portfolio
0.06%
Previous 0.07%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$36.12 - $43.96 $6.83 Million - $8.32 Million
-189,194 Reduced 13.66%
1,195,480 $47 Million
Q2 2024

Aug 14, 2024
SELL
$36.25 - $43.75 $2.38 Million - $2.87 Million
-65,668 Reduced 4.53%
1,384,674 $54 Million
Q1 2024

May 15, 2024
SELL
$42.66 - $50.04 $3.34 Million - $3.92 Million
-78,306 Reduced 5.12%
1,450,342 $62.4 Million
Q4 2023

Feb 14, 2024
SELL
$28.7 - $46.46 $18 Million - $29.1 Million
-625,746 Reduced 29.05%
1,528,648 $70.4 Million
Q3 2023

Nov 14, 2023
SELL
$34.16 - $39.73 $5.67 Million - $6.6 Million
-166,025 Reduced 7.15%
2,154,394 $73.6 Million
Q2 2023

Aug 14, 2023
SELL
$34.84 - $43.54 $5,818 - $7,271
-167 Reduced 0.01%
2,320,419 $89.3 Million
Q1 2023

May 15, 2023
SELL
$33.46 - $40.35 $1.53 Million - $1.84 Million
-45,592 Reduced 1.93%
2,320,586 $83.1 Million
Q4 2022

Feb 14, 2023
SELL
$33.06 - $39.43 $14.7 Million - $17.5 Million
-444,917 Reduced 15.83%
2,366,178 $93.3 Million
Q3 2022

Nov 14, 2022
BUY
$30.79 - $39.82 $25.3 Million - $32.7 Million
820,723 Added 41.23%
2,811,095 $101 Million
Q2 2022

Aug 15, 2022
BUY
$25.44 - $35.16 $11.6 Million - $16 Million
456,314 Added 29.75%
1,990,372 $60.5 Million
Q1 2022

May 16, 2022
BUY
$25.09 - $33.13 $7.86 Million - $10.4 Million
313,101 Added 25.64%
1,534,058 $46.9 Million
Q4 2021

Feb 14, 2022
BUY
$15.6 - $35.4 $18.6 Million - $42.2 Million
1,191,154 Added 3996.76%
1,220,957 $38.1 Million
Q3 2021

Nov 15, 2021
BUY
$14.86 - $19.45 $287,541 - $376,357
19,350 Added 185.11%
29,803 $456,000
Q2 2021

Aug 13, 2021
BUY
$16.81 - $20.0 $175,714 - $209,060
10,453 New
10,453 $195,000
Q4 2020

Feb 16, 2021
SELL
$9.49 - $16.04 $354,404 - $599,013
-37,345 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$10.82 - $13.35 $493,034 - $608,319
-45,567 Reduced 54.96%
37,345 $413,000
Q2 2020

Aug 13, 2020
BUY
$10.21 - $14.9 $846,531 - $1.24 Million
82,912 New
82,912 $1.04 Million
Q1 2020

May 15, 2020
SELL
$8.08 - $17.57 $392,736 - $854,007
-48,606 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$8.11 - $14.65 $394,194 - $712,077
48,606 New
48,606 $637,000

Others Institutions Holding XENE

# of Institutions
212
Shares Held
70.2M
Call Options Held
88.3K
Put Options Held
28.8K
View Full List

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email